1INTRODUCTIONMalignant pleural mesothelioma (MPM) is a rare but deadly malignant neoplasm arising in the pleura with approximately 2500 cases diagnosed annually in the United States and a median survival of 12 months (median survival in most series is 4–20 months). Asbestos exposure remains the greatest risk factor with 70–80% of MPM patients having documented exposure to asbestos: men are more commonly affected than women.The management of MPM is challenging and controversial. Broadly, there is debate regarding the optimal surgical approach of extrapleural pneumonectomy (EPP) versus lung sparing approaches, such as pleurectomy and decortication (P/D). Unfortunately, regardless of the surgical approach, relapse is common after surgery and is predominantly loco‐regional with subsequent dismal outcomes. Aggressive local therapy with surgery followed by adjuvant radiation plays a major role in the multimodal management to improve local control.The delivery of radiation therapy has improved over time from 3‐D conformal techniques to intensity modulated radiation therapy (IMRT). However, initial experience with IMRT was fraught with very high rates of fatal pulmonary toxicity. The increasing experience with IMRT treatment planning and delivery has improved our understanding of acceptable lung dose constraints. Strict adherence to these published lung dose constraints in subsequent studies has resulted in
Asia-Pacific Journal of Clinical Oncology – Wiley
Published: Jan 1, 2018
Keywords: ; ;
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.
Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.
It’s easy to organize your research with our built-in tools.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera